Business Overview
Beyond Air is a commercial-stage medical device and biopharmaceutical company developing nitric oxide (NO) generators and delivery systems under the LungFit platform. The company received FDA premarket approval for LungFit PH in June 2022 for treating persistent pulmonary hypertension of the newborn (PPHN) and obtained European CE mark approval in November 2024 for expanded indications including perioperative pulmonary hypertension. Beyond Air is expanding its commercial presence in the U.S. and internationally, with distribution agreements covering over 40 countries and regulatory approvals in more than 27 countries outside the U.S. and EU.
Forward Guidance
"We expect to incur losses for the next year." The company anticipates "significant contribution to revenues in fiscal 2027 and beyond" from international partnerships and distribution agreements. Management states "We believe the approval and subsequent launch of the LungFit PH II will equip our commercial organization to become the market leader in the U.S. in the near-term." The estimated total addressable market for inhaled NO is approximately "$350 million" in the U.S. and "$700 million or greater" worldwide.
Key Risk Factors
Going concern doubts expressed by independent accountants; substantial capital needs with dilutive funding requirements; commercialization risks including market acceptance uncertainty, intense competition, and inability to scale sales capabilities; regulatory risks including FDA approval for product candidates and compliance with healthcare laws; intellectual property risks including patent protection, enforcement costs, and third-party claims; and operational risks including reliance on third-party manufacturers, key personnel retention, and cybersecurity threats.
